Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2001 Jul 2;23(3):499–512. doi: 10.1016/S0149-2918(01)80053-9

Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy

Sanjay Saint a,b,c,, Kevin R Flaherty d, Paul Abrahamse e, Fernando J Martinez d, AMark Fendrick a,e
PMCID: PMC7133766  PMID: 11318083

Abstract

Background: Acute exacerbation of chronic bronchitis (AECB) is a common condition, with substantial associated costs and morbidity. Research efforts have focused on innovations that will reduce the morbidity associated with AECB. Health care payers increasingly expect that the results of evidence-based economic evaluations will guide practitioners in their choice of cost-effective interventions.

Objectives: To provide a framework on which to base effective and efficient antimicrobial therapy for AECB, we present a concise clinical review of AECB, followed by an assessment of the available data on the economic impact of this disease. We then address several AECB-specific issues that must be considered in cost-effectiveness analyses of AECB antimicrobial interventions.

Methods: Published literature on the clinical and economic impact of AECB was identified using MEDLINE®, pre-MEDLINE®, HealthSTAR, CINAHL, Current Contents/All Editions, EMBASE, and International Pharmaceutical Abstracts databases. Other potential sources were identified by searching for references in retrieved articles, review articles, consensus statements, and articles written by selected authorities.

Results: In evaluating cost-effectiveness analyses of AECB antimicrobial therapy it is critical to (1) use the disease-free interval as an outcome measure, (2) evaluate the sequence of multiple therapies, (3) address the impact of both current and future antibiotic resistance, and (4) measure all appropriate AECB-associated costs, both direct and indirect.

Conclusions: Incorporating these approaches in economic analyses of AECB antimicrobial therapy can help health care organizations make evidence-based decisions regarding the cost-effective management of AECB.

Keywords: lung diseases, obstructive; chronic bronchitis; costs; cost analysis

References

  • 1.American Thoracic Society Chronic bronchitis, asthma, and pulmonary emphysema: A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962;85:762–768. [Google Scholar]
  • 2.Centers for Disease Control and Prevention Current estimates from the national health interview survey, 1995. Vital and Health Statistics Series 10. 1998 No. 199. [PubMed] [Google Scholar]
  • 3.Sethi S. Infectious exacerbations of chronic bronchitis: Diagnosis and management. J Antimicrob Chemother. 1999;43:97–105. doi: 10.1093/jac/43.suppl_1.97. (Suppl A) [DOI] [PubMed] [Google Scholar]
  • 4.Nicolson P, Anderson P. The patient's burden: Physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 2000;45:25–32. doi: 10.1093/jac/45.suppl_2.25. [DOI] [PubMed] [Google Scholar]
  • 5.Niederman MS, McCombs JS, Unger AN. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther. 1999;21:576–591. doi: 10.1016/S0149-2918(00)88310-1. [DOI] [PubMed] [Google Scholar]
  • 6.Bloom BS, Smith WP, Weitz D, Lamont B. The diagnostic and treatment approach to two common conditions by the physician members of a community health maintenance organization. Am J Managed Care. 1997;3:733–736. [PubMed] [Google Scholar]
  • 7.National Heart, Lung, and Blood Institute Morbidity and Mortality Chartbook 2000. 2000 Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed. [Google Scholar]
  • 8.Gold MR, editor. Oxford University Press; New York: 1996. (Cost-Effectiveness in Health and Medicine). [Google Scholar]
  • 9.O'Byrne P, Postma DS. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:S41–S63. (Suppl 5) [PubMed] [Google Scholar]
  • 10.Niroumand M, Grossman RF. Airway infection. Infect Dis Clin North Am. 1998;12:671–688. doi: 10.1016/S0891-5520(05)70204-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Murphy TE, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;146:1067–1083. doi: 10.1164/ajrccm/146.4.1067. [DOI] [PubMed] [Google Scholar]
  • 12.Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345–1352. doi: 10.1378/chest.117.5.1345. [DOI] [PubMed] [Google Scholar]
  • 13.Mogulkoc N, Karakurt S, Isalska B. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med. 1999;160:349–353. doi: 10.1164/ajrccm.160.1.9809041. [DOI] [PubMed] [Google Scholar]
  • 14.Chodosh S, Schreurs A, Siami G. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. 1998;27:730–738. doi: 10.1086/514934. [DOI] [PubMed] [Google Scholar]
  • 15.Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid. Clin Ther. 1998;20:885–900. doi: 10.1016/s0149-2918(98)80071-4. [DOI] [PubMed] [Google Scholar]
  • 16.Buscho RO, Saxtan D, Shultz PS. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis. 1978;137:377–383. doi: 10.1093/infdis/137.4.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Smith CB, Golden CA, Kanner RE, Rensetti AD., Jr Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis. 1980;121:225–232. doi: 10.1164/arrd.1980.121.2.225. [DOI] [PubMed] [Google Scholar]
  • 18.Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108:43S–52S. doi: 10.1378/chest.108.2_Supplement.43S. (Suppl 1) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Eller J, Ede A, Schaberg T. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest. 1998;113:1542–1548. doi: 10.1378/chest.113.6.1542. [DOI] [PubMed] [Google Scholar]
  • 20.Miravitlles M, Espinosa C, Fernandez-Laso E. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46. doi: 10.1378/chest.116.1.40. [DOI] [PubMed] [Google Scholar]
  • 21.Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117:380S–385S. doi: 10.1378/chest.117.5_suppl_2.380s. (Suppl 2) [DOI] [PubMed] [Google Scholar]
  • 22.Ball P, Harris JM, Lowson D. Acute infective exacerbations of chronic bronchitis. QJM. 1995;88:61–68. [PubMed] [Google Scholar]
  • 23.Anthonisen NR, Manfreda J, Warren CP. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  • 24.Destache CJ, Dewan N, O'Donohue WI. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43:107–113. doi: 10.1093/jac/43.suppl_1.107. (Suppl A) [DOI] [PubMed] [Google Scholar]
  • 25.Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: Chronic bronchitis and emphysema. Respir Med. 2000;94:204–213. doi: 10.1053/rmed.1999.0720. [DOI] [PubMed] [Google Scholar]
  • 26.The European Study Group of Community Acquired Pneumonia (ESOCAP) of the European Respiratory Society. Schaberg T, Gialdroni-Grassi G, Huchon G. An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections. Thorax. 1996;51:1017–1022. doi: 10.1136/thx.51.10.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kessler R, Faller M, Fourgaut G. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:158–164. doi: 10.1164/ajrccm.159.1.9803117. [DOI] [PubMed] [Google Scholar]
  • 28.Niewoehner DE, Erbland ML, Deupree RH. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941–1947. doi: 10.1056/NEJM199906243402502. [DOI] [PubMed] [Google Scholar]
  • 29.Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273:957–960. [PubMed] [Google Scholar]
  • 30.Dewan NA, Rafique S, Kanwar B. Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest. 2000;117:662–671. doi: 10.1378/chest.117.3.662. [DOI] [PubMed] [Google Scholar]
  • 31.Wilson R, Wilson CB. Defining subsets of patients with chronic bronchitis. Chest. 1997;112:303S–309S. doi: 10.1378/chest.112.6_supplement.303s. (Suppl 6) [DOI] [PubMed] [Google Scholar]
  • 32.Wilson R. Outcome predictors in bronchitis. Chest. 1995;106:53S–57S. doi: 10.1378/chest.108.2_supplement.53s. (Suppl 1) [DOI] [PubMed] [Google Scholar]
  • 33.Grossman RF. Cost-effective therapy for acute exacerbations of chronic bronchitis. Semin Respir Infect. 2000;15:71–81. doi: 10.1053/srin.2000.0150071. [DOI] [PubMed] [Google Scholar]
  • 34.Lode H. Respiratory tract infections: When is antibiotic therapy indicated? Clin Ther. 1991;13:149–156. [PubMed] [Google Scholar]
  • 35.Balter M, Hyland R, Low D. Recommendations on the management of chronic bronchitis. Can Med Assoc J. 1994;151:7–23. (Suppl) [Google Scholar]
  • 36.van Barlingen H, Nuijten M, Volmer T. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J Drug Assess. 1998;1:695–711. [Google Scholar]
  • 37.Quenzer RW, Pettit KG, Arnold RJ, Kaniecki DJ. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Am J Managed Care. 1997;3:1027–1036. [PubMed] [Google Scholar]
  • 38.Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. Br J Med Econ. 1995;8:11–25. [Google Scholar]
  • 39.The Canadian Ciprofloxacin Health Economic Study Group. Grossman R, Mukherjee J, Vaughan D. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 1998;113:131–141. doi: 10.1378/chest.113.1.131. [DOI] [PubMed] [Google Scholar]
  • 40.Torrance G, Walker V, Grossman R. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics. 1999;16:499–520. doi: 10.2165/00019053-199916050-00007. [DOI] [PubMed] [Google Scholar]
  • 41.Gonzales R, Corbett K. The culture of antibiotics. Am J Med. 1999;107:525–526. doi: 10.1016/s0002-9343(99)00302-2. Editorial. [DOI] [PubMed] [Google Scholar]
  • 42.Hong JS, Philbrick JT, Schorling JB. Treatment of upper respiratory infections: Do patients really want antibiotics? Am J Med. 1999;107:511–515. doi: 10.1016/s0002-9343(99)00270-3. [DOI] [PubMed] [Google Scholar]
  • 43.Wilson AA, Crane LA, Barrett PH, Gonzales R. Public beliefs and use of antibiotics for acute respiratory illness. J Gen Intern Med. 1999;14:658–662. doi: 10.1046/j.1525-1497.1999.08118.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med. 2000;133:128–135. doi: 10.7326/0003-4819-133-2-200007180-00012. [DOI] [PubMed] [Google Scholar]
  • 45.Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117:5S–9S. doi: 10.1378/chest.117.2_suppl.5s. (Suppl 2) [DOI] [PubMed] [Google Scholar]
  • 46.Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: Its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis. 1999;28:1344–1345. doi: 10.1086/517802. Letter. [DOI] [PubMed] [Google Scholar]
  • 47.Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med. 1991;91:87S–92S. doi: 10.1016/0002-9343(91)90317-q. [DOI] [PubMed] [Google Scholar]
  • 48.Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med. 1987;82:154–163. [PubMed] [Google Scholar]
  • 49.Wool C, Cerutti R, Garbagna N, Grossi E. A cost-effectiveness study of four different antibiotics in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Br J Med Econ. 1996;10:159–168. [Google Scholar]
  • 50.Doern GV, Pfaller MA, Kugler K. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764–770. doi: 10.1086/514953. [DOI] [PubMed] [Google Scholar]
  • 51.Gotfried MH. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Clin Ther. 2000;22:2–14. doi: 10.1016/s0149-2918(00)87973-4. [DOI] [PubMed] [Google Scholar]
  • 52.Chenoweth CE, Saint S, Martinez F. Antimicrobial resistance in Streptococcus pneumoniae: Implications for patients with community-acquired pneumonia. Mayo Clin Proc. 2000;75:1161–1168. doi: 10.4065/75.11.1161. [DOI] [PubMed] [Google Scholar]
  • 53.Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233–239. doi: 10.1056/NEJM199907223410403. [DOI] [PubMed] [Google Scholar]
  • 54.Seppala H, Klaukka T, Vuopio-Varkila J. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 1997;337:441–446. doi: 10.1056/NEJM199708143370701. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Therapeutics are provided here courtesy of Elsevier

RESOURCES